SALT Trial: Steroids after Laser Trabeculoplasty: Impact of Short-Term Anti-inflammatory Treatment on Selective Laser Trabeculoplasty Efficacy.
Administration, Ophthalmic
Aged
Anti-Inflammatory Agents, Non-Steroidal
/ therapeutic use
Double-Blind Method
Female
Glaucoma, Open-Angle
/ physiopathology
Glucocorticoids
/ therapeutic use
Humans
Intraocular Pressure
/ physiology
Ketorolac
/ therapeutic use
Laser Therapy
/ methods
Male
Middle Aged
Ocular Hypertension
/ drug therapy
Ophthalmic Solutions
Postoperative Period
Prednisolone
/ therapeutic use
Tonometry, Ocular
Trabecular Meshwork
/ surgery
Trabeculectomy
/ methods
Treatment Outcome
Journal
Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
12
11
2018
revised:
25
04
2019
accepted:
28
05
2019
pubmed:
25
8
2019
medline:
14
3
2020
entrez:
25
8
2019
Statut:
ppublish
Résumé
This study examined whether short-term use of topical nonsteroidal anti-inflammatory drug (NSAID) or steroid therapy affected the efficacy of selective laser trabeculoplasty (SLT). Double-masked, randomized, placebo-controlled, dual-center, multisurgeon trial. Patients older than 18 years with intraocular pressure (IOP) of more than 18 mmHg for whom the clinician decided SLT was the appropriately indicated therapy were randomized to 1 of 3 groups in a ratio of 1:1:1 as follows: ketorolac 0.5%, prednisolone 1%, or saline tears. After SLT, patients randomized into each group were instructed to use an unmarked drop 4 times daily starting the day of SLT and continuing for 4 additional days. The Kruskal-Wallis test and Wilcoxon rank-sum test were used for continuous variables when comparing 2 or 3 treatment groups, respectively. The Fisher exact test was used for categorical variables. The primary outcome of this study was IOP at 12 weeks. Secondary outcome measures included IOP at 1 and 6 weeks, patient-reported pain, and detectable anterior chamber inflammation. Ninety-six eyes of 85 patients fit inclusion criteria and were enrolled between the 2 sites. The NSAID, steroid, and placebo groups were similar in baseline demographics and baseline IOP (mean, 23.3±3.9 mmHg; P = 0.57). There was no statistically significant difference in IOP decrease among groups at week 6. Both the NSAID and steroid groups showed a statistically significantly greater decrease in IOP at week 12 compared with the placebo group (mean, -6.2±3.1 mmHg, -5.2±2.7 mmHg, and -3±4.3 mmHg, respectively; P = 0.02 [analysis of variance] and P = 0.002 [t test] for NSAID vs. placebo groups; P = 0.02 for steroid vs. placebo groups). Significantly better IOP reduction at 12 weeks was measured in eyes treated with steroid or NSAID drops after SLT. Short-term postoperative use of NSAID or steroid drops may improve IOP reduction after SLT. Longer-term follow-up studies are indicated.
Identifiants
pubmed: 31444008
pii: S0161-6420(18)32934-8
doi: 10.1016/j.ophtha.2019.05.032
pmc: PMC6810843
mid: NIHMS1538077
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Glucocorticoids
0
Ophthalmic Solutions
0
Prednisolone
9PHQ9Y1OLM
Ketorolac
YZI5105V0L
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1511-1516Subventions
Organisme : NEI NIH HHS
ID : P30 EY022589
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY026877
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Published by Elsevier Inc.
Références
Arch Ophthalmol. 1988 Apr;106(4):544-7
pubmed: 3355425
Br J Ophthalmol. 2005 Sep;89(9):1157-60
pubmed: 16113372
Br J Ophthalmol. 1999 Jun;83(6):718-22
pubmed: 10340983
Arch Ophthalmol. 1993 Apr;111(4):481-3
pubmed: 8470978
Ophthalmol Ther. 2013 Dec;2(2):113-20
pubmed: 25135811
Can J Ophthalmol. 2007 Oct;42(5):715-9
pubmed: 17891199
Arch Ophthalmol. 1979 Feb;97(2):319-22
pubmed: 575877
Am J Ophthalmol. 1996 Sep;122(3):349-54
pubmed: 8794707
Br J Ophthalmol. 1999 Jan;83(1):29-32
pubmed: 10209430
Trans Am Ophthalmol Soc. 1983;81:325-32
pubmed: 6676975
Arch Ophthalmol. 1989 Apr;107(4):572-6
pubmed: 2705927
Ophthalmologica. 2004 Jan-Feb;218(1):20-5
pubmed: 14688431
Ophthalmic Surg Lasers Imaging. 2010 Jan-Feb;41(1):100-3
pubmed: 20128578
Exp Eye Res. 1995 Apr;60(4):359-71
pubmed: 7789416
Arch Ophthalmol. 1985 Oct;103(10):1546-52
pubmed: 4051857
Eur J Ophthalmol. 2002 Jul-Aug;12(4):287-92
pubmed: 12219998
Arch Ophthalmol. 1983 Mar;101(3):382-4
pubmed: 6830487
Graefes Arch Clin Exp Ophthalmol. 1995 Sep;233(9):559-62
pubmed: 8543206
BMC Ophthalmol. 2008 Oct 21;8:20
pubmed: 18939999
Br J Ophthalmol. 2006 Dec;90(12):1490-4
pubmed: 16899528
Clin Exp Ophthalmol. 2004 Aug;32(4):368-72
pubmed: 15281969
Ophthalmol Clin North Am. 2005 Sep;18(3):409-19, vi
pubmed: 16054998
Ophthalmology. 2014 Dec;121(12):2356-61
pubmed: 25234015
Curr Opin Ophthalmol. 2007 Mar;18(2):140-5
pubmed: 17301616
Br J Ophthalmol. 2005 Nov;89(11):1413-7
pubmed: 16234442
Eur J Ophthalmol. 2006 Jan-Feb;16(1):100-4
pubmed: 16496252
J Ophthalmol. 2012;2012:642869
pubmed: 22900148
Ophthalmology. 1984 Sep;91(9):1005-10
pubmed: 6493712
Invest Ophthalmol Vis Sci. 2000 Feb;41(2):422-30
pubmed: 10670472
Ophthalmologica. 2001 Jul-Aug;215(4):267-70
pubmed: 11399933
Am J Ophthalmol. 2005 Sep;140(3):524-5
pubmed: 16139003
J Glaucoma. 2017 Feb;26(2):e22-e29
pubmed: 27552500